TRAXNasdaqPharmaceutical PreparationsFiscal year ends December 31
First Tracks Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$36.28+1.82 (+5.28%)
Close on Oct 19, 2026
- Market cap
- $1.27B
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
92.0%
33M of 36M shares
Institutional holders
149
149 new, 0 sold out
Net institutional buying
33M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $66.74M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| EcoR1 Capital, LLC | 3,174,519 | 9.10% | 13G (passive) | Apr 20, 2026 |
| Chen Yu | 2,895,304 | 8.30% | 13G (passive) | Jun 30, 2026 |
| Alex Silverstein | 2,495,777 | 7.20% | 13G (passive) | Jun 30, 2026 |
| FMR LLC | 2,054,127 | 5.90% | 13G (passive) | Jun 30, 2026 |
| Michael Cho | 2,032,012 | 5.80% | 13G (passive) | Jun 30, 2026 |
| BlackRock, Inc. | 1,919,376 | 5.50% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TRAX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EcoR1 Capital, LLC | 3,174,519 | 8.88% | $63.87M | New | 3.11% |
| TCG Crossover Management, LLC | 2,895,304 | 8.10% | $58.25M | New | 1.40% |
| FMR LLC | 2,054,127 | 5.75% | $41.33M | New | 0.00% |
| Affinity Asset Advisors, LLC | 2,032,012 | 5.69% | $40.88M | New | 1.85% |
| BlackRock, Inc. | 1,963,541 | 5.50% | $39.51M | New | 0.00% |
| Trails Edge Capital Partners, LP | 1,514,000 | 4.24% | $30.46M | New | 4.84% |
| Vanguard Capital Management LLC | 1,451,909 | 4.06% | $29.21M | New | 0.00% |
| Jupiter Topco LLC | 1,091,464 | 3.05% | $21.96M | New | 0.01% |
| Vestal Point Capital, LP | 1,013,000 | 2.84% | $20.38M | New | 0.48% |
| Woodline Partners LP | 917,176 | 2.57% | $18.45M | New | 0.06% |
| Sanofi | 821,917 | 2.30% | $16.54M | New | 3.10% |
| Morgan Stanley | 781,534 | 2.19% | $15.72M | New | 0.00% |
| 683 Capital Management, LLC | 750,000 | 2.10% | $15.09M | New | 0.74% |
| Adage Capital Partners Gp, L.L.C. | 729,000 | 2.04% | $14.67M | New | 0.02% |
| Balyasny Asset Management L.P. | 714,948 | 2.00% | $14.38M | New | 0.02% |
| Geode Capital Management, LLC | 702,087 | 1.96% | $14.13M | New | 0.00% |
| Bank Of America Corp /De/ | 647,962 | 1.81% | $13.04M | New | 0.00% |
| Stempoint Capital LP | 622,723 | 1.74% | $12.53M | New | 2.16% |
| Palo Alto Investors LP | 603,489 | 1.69% | $12.14M | New | 1.68% |
| Sofinnova Investments, Inc. | 565,199 | 1.58% | $11.37M | New | 0.59% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 149 | 33M | 92.0% | 149 / 0 | 0 / 0 | 33M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of TRAX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1,111,470 | 3.11% | $22.36M | 0.00% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 930,353 | 2.60% | $18.72M | 0.17% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 607,976 | 1.70% | $12.23M | 0.01% | Jun 30, 2026 |
| Select Health Care Portfolio | 400,000 | 1.12% | $6.38M | 0.11% | May 31, 2026 |
| Fidelity Advisor Biotechnology Fund | 341,150 | 0.95% | $15.02M | 0.68% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 309,285 | 0.87% | $6.22M | 0.01% | Jun 30, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 290,000 | 0.81% | $12.77M | 0.45% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 255,152 | 0.71% | $11.24M | 0.03% | Jul 31, 2026 |
| Fidelity Advisor Health Care Fund | 200,000 | 0.56% | $8.81M | 0.28% | Jul 31, 2026 |
| Victory Science & Technology Fund | 187,893 | 0.53% | $8.27M | 0.55% | Jul 31, 2026 |
| Vanguard Strategic Equity Fund | 153,153 | 0.43% | $3.08M | 0.03% | Jun 30, 2026 |
| Fidelity Series Small Cap Core Fund | 152,800 | 0.43% | $6.73M | 0.43% | Jul 31, 2026 |
| iShares Russell 2000 Growth ETF | 150,721 | 0.42% | $3.03M | 0.02% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 101,699 | 0.28% | $1.62M | 0.00% | May 31, 2026 |
| Vanguard Explorer Fund | 98,262 | 0.28% | $4.33M | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Daniel Faga | President, CEO, Director | 496,684 | 1.39% | Aug 18, 2026 |
| Paul F. Lizzul | Chief Medical Officer | 42,669 | 0.12% | Aug 18, 2026 |
| Benjamin Stone | Chief Business Officer | 17,262 | 0.05% | Aug 18, 2026 |
| Ajim Tamboli | Chief Financial Officer | – | – | May 14, 2026 |
| John A. Orwin | Director | 17,995 | 0.05% | Sep 17, 2026 |
| J. Anthony Ware | Director | 15,660 | 0.04% | Sep 4, 2026 |
| Rita Jain | Director | 19,194 | 0.05% | Jun 17, 2026 |
| John P. Schmid | Director | 37,652 | 0.11% | Jun 17, 2026 |
| Dennis M. Fenton | Director | 10,995 | 0.03% | Jun 17, 2026 |
| Magda Marquet | Director | 15,960 | 0.04% | Jun 17, 2026 |
| EcoR1 Capital, LLC | 10% owner | 7,880,094 | 22.05% | Apr 22, 2026 |
| Anaptysbio, Inc | 10% owner | 0 | – | Apr 22, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| John A. Orwin Director | Sep 15, 2026 | Option exercise | +1,300 | – | – | 17,995 |
| J. Anthony Ware Director | Sep 2, 2026 | Sale | −39,265 | $44.78 | $1.76M | 15,660 |
| J. Anthony Ware Director | Sep 2, 2026 | Option exercise | +39,265 | $5.74 | $225.38K | 54,925 |
| John P. Schmid Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 37,652 |
| J. Anthony Ware Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 15,660 |
| Magda Marquet Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 15,960 |
| Rita Jain Director | Jun 15, 2026 | Option exercise | +7,330 | – | – | 19,194 |
| John A. Orwin Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 16,695 |
| Dennis M. Fenton Director | Jun 15, 2026 | Option exercise | +6,030 | – | – | 10,995 |
| EcoR1 Capital, LLC 10% owner | Apr 20, 2026 | Sale | +4,705,575 | $13.81 | $64.98M | 3,174,519 |
| Anaptysbio, Inc 10% owner | Apr 20, 2026 | Other | −100 | – | – | 0 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Anthony Ware Joe Director | Sep 2, 2026 | 39,265 | $1.76M | Sep 2, 2026 | Stock Option Exercise |